LX-1031, a tryptophan 5-hydroxylase inhibitor, and its potential in chronic diarrhea associated with increased serotonin

Serotonin in the gastrointestinal tract

(2011) Michael Camilleri   Current Opinion in Endocrinology Diabetes and Obesity

Ischemic Colitis and Complications of Constipation Associated With the Use of Alosetron Under a Risk Management Plan: Clinical Characteristics, Outcomes and Incidences

(2010) Lin Chang et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Evolution of Clinical Trials for Irritable Bowel Syndrome: Issues in End Points and Study Design

(2010) Ann Marie Trentacosti et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Serotonin Signaling Is Altered in Irritable Bowel Syndrome With Diarrhea but Not in Functional Dyspepsia in Pediatric Age Patients

(2010) Christophe Faure et al.   GASTROENTEROLOGY

Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis

(2010) Vijay K Yadav et al.   NATURE MEDICINE

5-HT4 receptor agonists: similar but not the same

(2010) J. H. De Maeyer et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Review article: new receptor targets for medical therapy in irritable bowel syndrome

(2009) M. CAMILLERI   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Substituted 3-(4-(1,3,5-triazin-2-yl)-phenyl)-2-aminopropanoic acids as novel tryptophan hydroxylase inhibitors

(2009) Haihong Jin et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Effects of Chenodeoxycholate and a Bile Acid Sequestrant, Colesevelam, on Intestinal Transit and Bowel Function

(2009) Suwebatu T. Odunsi–Shiyanbade et al.   Clinical Gastroenterology and Hepatology

Effects of 5-Hydroxytryptamine (Serotonin) Type 3 Antagonists on Symptom Relief and Constipation in Nonconstipated Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

(2008) Viola Andresen et al.   Clinical Gastroenterology and Hepatology

A Phase II Trial of the Novel Serotonin Type 3 Receptor Antagonist Ramosetron in Japanese Male and Female Patients with Diarrhea-Predominant Irritable Bowel Syndrome

(2008) K. Matsueda et al.   DIGESTION

Challenges to the Therapeutic Pipeline for Irritable Bowel Syndrome: End Points and Regulatory Hurdles

(2008) Michael Camilleri et al.   GASTROENTEROLOGY

First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome

(2008) Johannes Kapeller et al.   HUMAN MOLECULAR GENETICS

Modulation of Peripheral Serotonin Levels by Novel Tryptophan Hydroxylase Inhibitors for the Potential Treatment of Functional Gastrointestinal Disorders

(2008) Zhi-Cai Shi et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery and Characterization of Novel Tryptophan Hydroxylase Inhibitors That Selectively Inhibit Serotonin Synthesis in the Gastrointestinal Tract

(2008) Q. Liu et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Trypsinogen IV, serotonin transporter transcript levels and serotonin content are increased in small intestine of irritable bowel syndrome patients

(2008) a. p. m. kerckhoffs et al.   NEUROGASTROENTEROLOGY AND MOTILITY

A Placebo-Controlled Trial of Prucalopride for Severe Chronic Constipation

(2008) Michael Camilleri et al.   NEW ENGLAND JOURNAL OF MEDICINE

A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome

(2008) Kei Matsueda et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY